openPR Logo
Press release

Registration opens for SMi’s 4th Annual Ophthalmic Drugs Conference

06-25-2020 04:49 PM CET | Health & Medicine

Press release from: SMi Group

Registration opens for SMi’s 4th Annual Ophthalmic Drugs

SMi reports: Registration is now open for the 4th annual Ophthalmic Drugs Conference, taking place in London on the 23rd-24th November 2020.

SMi presents the 4th Annual Ophthalmic Drugs Conference taking place on the 23rd-24th of November 2020, in London.

The global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy. With 50% of the global population predicted to have complications in their sight within the next few decades, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals.

The newly-released brochure with the three-day agenda and full speaker line-up is available to download online at www.ophthalmicdrugs.com/pr1openpr

As Europe’s leading Ophthalmic Drugs conference, the conference will explore new discoveries in the treatment of ocular disease, innovations in combination technologies, and the utterly unique challenges that are faced in the treatment of one of the most complex organs in the body.

Chair For 2020:

• Mitchell de Long, Vice President, Chemistry, Aerie Pharmaceuticals

Featured 2020 Speakers Include:

• Magali Taiel, Chief Medical Officer, Gensight-Biologics
• Alan Franklin, CEO, Forward Vue Pharma
• Brian Levy, CEO, Ocunexus Therapeutics
• Victor Chong, Global Medical Head, Retinal Health, Boehringer Ingelheim International GmbH
• Harminder Dua, Chair and Professor of Ophthalmology, University of Nottingham
• Ian Catchpole, Chief Scientific Officer, Horama
• Francine Behar-Cohen, Chief Innovation Officer, Eyevensys
• Dr Thakur Raghu Raj Singh, Reader in Pharmaceutics, Queen’s University Belfast

Highlights For 2020:
• INSIGHT into the newest techniques in ocular drug design and delivery
• EXPLORE the impacts and applications of controlled release technologies
• LEARN how advanced medical devices are changing the face of combined therapy
• UNDERSTAND the latest developments in overcoming the challenge of treating such a complex organs

This two-day agenda will offer peer-to-peer networking opportunities with leaders in the ophthalmic sphere, from Heads of Drug Development and Senior Directors of Ophthalmology, all the way to academic forerunners in the research into ocular therapy

Registration is now open for interested parties at www.ophthalmicdrugs.com/pr1openpr

Ophthalmic Drugs Conference
23rd-24th November 2020
Holiday Inn Kensington High Street, London, UK
#OphthalmicDrugs
For exclusive tailored sponsorship/table-top opportunities contact: Alia Malick on +44 (0)20 7827 6168 or email amalick@smi-online.co.uk
For media queries please contact Jinna Sidhu at hsidhu@smi-online.co.uk or call +44 (0)20 7827 6088

---End---

Ground Floor, India House, 45 Curlew Street
London, SE1 2ND
Jinna Sidhu

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Registration opens for SMi’s 4th Annual Ophthalmic Drugs Conference here

News-ID: 2080455 • Views: 547

More Releases from SMi Group

Registration is open for SMi’s 5th Annual Pharmaceutical Microbiology East Coa …
SMi Group reports: The 5th Annual Pharmaceutical Microbiology East Coast Conference is set to return in April 2022 with a key focus existing methods and novel tools in microbial control to assure continuity in product quality and patient safety. SMi Group is delighted to announce the 5th Annual Pharmaceutical Microbiology East Coast Conference, taking place on the 27th and 28th April 2022 in Boston, USA. The 2022 Conference theme is
SMi’s 10th Annual Pharmaceutical Microbiology UK Conference - A Virtual Confer …
SMi Reports: SMi Group have made the decision to open the microbiology conference and workshops to all microbiologists by transforming it into a virtual-remote online access event only on 17th and 18th January 2022. SMi’s 10th Annual Pharmaceutical Microbiology UK Conference will no longer take place in London, UK. Instead, the conference is taking place on 17 and 18 January 2022 and will open its doors to a global audience delivering
Co-chairs Philip Hewitt and Stefan Pryzyborski, invitation to join SMi’s 5th A …
SMi Group reports: Co-Chairs, Philip Hewitt and Stefan Pryzyborski for SMi’s 5th Annual 3D Cell Culture invite industry professionals to join the conference in February 2022. Philip Hewitt, Global Head of Early Investigative Toxicology, Merck and Stefan Przyborski, Professor in Cell Technology, Durham University invite industry professionals by releasing invite letter to join SMi’s 5th Annual 3D Cell Culture Conference 2022. This event will convene on February 9th – 10th 2022,
7 Key Takeaways from SMi’s 10th Annual Pharmaceutical Microbiology Conference
SMi Reports: SMi Group outlines seven key takeaways attendees can gain from joining the Pharmaceutical Microbiology Conference on 17 and 18 January 2021 in London, UK. The 10th Annual Pharmaceutical Microbiology Conference will convene on the 17th and 18th January 2022 in London, UK. Developing on previous conference success, SMi's 10th Annual Pharmaceutical Microbiology Conference will bring together industry experts to discuss and analyse the latest advancements and challenges

All 5 Releases


More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Drug and cosmetics
Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop. DRug and cosmetics BLESSY MATHEW Program
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning